Cytosorbents Corporation (NASDAQ:CTSO) has been given an average rating of “Buy” by the seven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $12.71.
Several equities analysts have recently commented on CTSO shares. Aegis reiterated a “buy” rating and set a $9.00 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Maxim Group reiterated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents Corporation in a research report on Wednesday, July 5th. ValuEngine upgraded Cytosorbents Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Cowen and Company started coverage on Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, HC Wainwright set a $13.00 price objective on Cytosorbents Corporation and gave the company a “buy” rating in a research report on Tuesday, August 8th.
Several institutional investors have recently made changes to their positions in the company. Skylands Capital LLC grew its position in Cytosorbents Corporation by 87.7% during the 2nd quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock worth $2,555,000 after acquiring an additional 277,650 shares during the last quarter. Sabby Management LLC bought a new position in Cytosorbents Corporation during the 1st quarter worth approximately $990,000. Cowen Group Inc. bought a new position in Cytosorbents Corporation during the 1st quarter worth approximately $248,000. PNC Financial Services Group Inc. grew its position in Cytosorbents Corporation by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Segantii Capital Management Ltd grew its position in Cytosorbents Corporation by 563.4% during the 1st quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after acquiring an additional 23,100 shares during the last quarter. Hedge funds and other institutional investors own 6.89% of the company’s stock.
Cytosorbents Corporation (NASDAQ:CTSO) traded up 0.91% during mid-day trading on Friday, hitting $5.55. The stock had a trading volume of 51,301 shares. Cytosorbents Corporation has a 52 week low of $3.30 and a 52 week high of $6.90. The firm’s market cap is $156.14 million. The company’s 50 day moving average price is $5.14 and its 200 day moving average price is $4.78.
Cytosorbents Corporation (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. Analysts anticipate that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.